Allogene Therapeutics, Inc.

Ownership Transactions Reported by 22 Insiders

Symbol
ALLO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
210 East Grand Avenue, South San Francisco, CA

Insiders trading volume in the past year

Allogene Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Tpg Gp A, Llc 10%+ Owner $59.4M Jan 12, 2022
David D. Chang President and CEO, Director $27.2M May 16, 2024
Arie Belldegrun Director $17.6M +$5M +39.6% May 16, 2024
Eric Schmidt Chief Financial Officer $10.6M Mar 22, 2023
Zachary Roberts EVP of R&D $6.4M Jan 25, 2024
Alison Moore Chief Technical Officer $6.3M Mar 22, 2023
Rafael Amado EVP of R&D $5.27M Oct 7, 2022
Veer Bhavnagri General Counsel $4.39M Mar 14, 2023
Geoffrey M. Parker Chief Financial Officer $4.38M +$683 +0.02% May 16, 2024
Timothy L. Moore Chief Technical Officer $4.21M Apr 22, 2024
N. Witte Director $2.77M Jun 5, 2024
Earl Douglas SVP, General Counsel $2.67M Aug 21, 2024
Stephen Mayo Director $1.92M Jun 5, 2024
Elizabeth Barrett Director $1.84M Jun 5, 2024
Joshua A. Kazam Director $1.84M Jun 5, 2024
Franz B. Humer Director $1.66M -$26.2K -1.55% Jun 5, 2024
Vicki L. Sato Director $1.3M Jun 5, 2024
Yinlin Jack Chen SVP, Finance $659K Aug 10, 2023
Lillian Smith VP, Corporate Counsel $446K Apr 1, 2023
Deborah M. Messemer Director $380K -$92.8K -19.6% Jun 18, 2024
Annie Yoshiyama SVP, Finance $238K Jun 5, 2024
PF Equity Holdings 2 B.V. 10%+ Owner Mar 31, 2022

Recent Insider Transactions by Companies or Individuals for Allogene Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.